PPARG and Insulin resistance: Pioglitazone and rosiglitazone, known as thiazolidinediones (TZDs), activating peroxisome proliferator-activated receptor gamma (PPARγ), reduce the extent of insulin resistance and improve β-cell response towards altered glucose levels.